Clinical Trials Logo

Clinical Trial Summary

This phase Ib trial studies the side effects and best dose of ribociclib when giving together with doxorubicin hydrochloride in treating patients with soft tissue sarcomas that has spread to other places or that cannot be removed by surgery (advanced). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib and doxorubicin hydrochloride may work better in treating patients with soft tissue sarcoma.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine the recommended phase 2 dose (RP2D) of ribociclib in combination with doxorubicin in subjects with advanced soft tissue sarcomas. SECONDARY OBJECTIVES: I. To assess preliminary anti-tumor activity of ribociclib in combination with doxorubicin in subjects with advanced soft tissue sarcomas. II. To characterize the safety and tolerability of ribociclib in combination with doxorubicin. OUTLINE: This is a dose-escalation study of ribociclib. Patients receive ribociclib orally (PO) daily on days 1-7, and doxorubicin hydrochloride intravenously (IV) on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients without disease progression after 6 cycles receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up within 30 days and then every 12 weeks for 12 months. ;


Study Design


Related Conditions & MeSH terms

  • Advanced Soft Tissue Sarcoma
  • Fibrosarcoma
  • Histiocytoma, Malignant Fibrous
  • Leiomyosarcoma
  • Liposarcoma
  • Locally Advanced Angiosarcoma
  • Locally Advanced Leiomyosarcoma
  • Locally Advanced Liposarcoma
  • Locally Advanced Malignant Peripheral Nerve Sheath Tumor
  • Locally Advanced Myxofibrosarcoma
  • Locally Advanced Undifferentiated Pleomorphic Sarcoma
  • Metastatic Angiosarcoma
  • Metastatic Epithelioid Sarcoma
  • Metastatic Fibrosarcoma
  • Metastatic Liposarcoma
  • Metastatic Malignant Peripheral Nerve Sheath Tumor
  • Metastatic Myxofibrosarcoma
  • Metastatic Soft Tissue Sarcoma
  • Metastatic Synovial Sarcoma
  • Metastatic Undifferentiated Pleomorphic Sarcoma
  • Myxofibrosarcoma
  • Nerve Sheath Neoplasms
  • Pleomorphic Rhabdomyosarcoma
  • Rhabdomyosarcoma
  • Sarcoma
  • Sarcoma, Synovial
  • Stage III Soft Tissue Sarcoma AJCC v7
  • Stage IV Soft Tissue Sarcoma AJCC v7
  • Undifferentiated (Embryonal) Sarcoma
  • Unresectable Leiomyosarcoma
  • Unresectable Liposarcoma
  • Unresectable Malignant Peripheral Nerve Sheath Tumor
  • Unresectable Soft Tissue Sarcoma
  • Unresectable Synovial Sarcoma
  • Unresectable Undifferentiated Pleomorphic Sarcoma

NCT number NCT03009201
Study type Interventional
Source OHSU Knight Cancer Institute
Contact
Status Active, not recruiting
Phase Phase 1
Start date March 10, 2017
Completion date June 30, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03670069 - Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas Phase 1
Recruiting NCT03793361 - Phase II Study of Regorafenib as Maintenance Therapy Phase 2
Withdrawn NCT03397186 - Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma Phase 2
Active, not recruiting NCT02500797 - Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Phase 2
Recruiting NCT03965234 - Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Soft Tissue or Bone Sarcoma Metastatic to the Lungs Phase 1/Phase 2
Recruiting NCT04028063 - Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas Phase 2
Recruiting NCT04200443 - Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma Phase 2
Active, not recruiting NCT01514188 - Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma Phase 2
Completed NCT01574716 - Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation Phase 2
Recruiting NCT03138161 - SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT03660930 - Nanoparticle Albumin-Bound Rapamycin and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas Phase 1/Phase 2